Survival outcomes for various treatment modalities in advanced-stage grade 3 follicular lymphoma (FL3): A National Cancer Database (NCDB) study.

被引:0
|
作者
Giri, Upama
Vick, Eric
Lee, Sophia SeoHyeon
Altahan, Alaa
VanderWalde, Noam Avraham
Dickson, Paxton Vandiver
Deneve, Jeremiah Lee
Martin, Michael Gary
机构
[1] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA
[2] Univ Tennessee, Dept Radiat Oncol, West Canc Ctr, Hlth Sci Ctr, Memphis, TN 38163 USA
[3] Univ Tennessee, Div Surg Oncol, Dept Surg, West Canc Ctr,Hlth Sci Ctr, Memphis, TN 38163 USA
[4] Univ Tennessee, Dept Hematol Oncol, West Canc Ctr, Hlth Sci Ctr, Memphis, TN 38163 USA
关键词
D O I
10.1200/JCO.2017.35.15_suppl.7554
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
7554
引用
收藏
页数:6
相关论文
共 39 条
  • [1] Survival outcomes for various treatment modalities in early-stage grade 3 follicular lymphoma (FL3): a National Cancer Database (NCDB) study.
    Giri, Upama
    Vick, Eric
    Lee, Sophia SeoHyeon
    Altahan, Alaa
    VanderWalde, Noam Avraham
    Dickson, Paxton Vandiver
    Deneve, Jeremiah Lee
    Martin, Michael Gary
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Initial Treatment Vs Watch and Wait in Advanced-Stage Follicular Lymphoma in the Rituximab Era - an Analysis of the National Cancer Database (NCDB)
    Dong, Ning
    Saeed, Hayder
    Isenalumhe, Leidy
    Tokumori, Franco Castillo
    Shah, Bijal
    Gaballa, Sameh
    Bello, Celeste
    Sokol, Lubomir
    Ibarz, Javier Pinilla
    Chavez, Julio C.
    BLOOD, 2020, 136
  • [3] Does An Anthracycline Make a Difference for Follicular Lymphoma (FL) Grade 3? Patterns of Care and Treatment Outcomes of Grade 3 FL From the National LymphoCare Study (NLCS)
    Flowers, Christopher R.
    Taylor, Michael
    Byrtek, Michelle
    Hirata, Jamie H.
    Cerhan, James
    Hainsworth, John
    Link, Brian
    Miller, Thomas P.
    Dillon, Hildy
    Friedberg, Jonathan W.
    BLOOD, 2010, 116 (21) : 737 - 737
  • [4] Treatment Outcomes of Limited Stage Grade 3A Follicular Lymphoma
    Sarkar, Reith R.
    Lee, Jasme
    Zhang, Zhigang
    Zelenetz, Andrew D.
    Salles, Gilles
    Yahalom, Joachim
    Imber, Brandon S.
    BLOOD, 2023, 142
  • [5] Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen
    Shah, Nirav N.
    Szabo, Aniko
    Saba, Raya
    Strelec, Lauren
    Kodali, Dheeraj
    Vaughn, John L.
    Esan, Olukemi
    Yang, David T.
    Mato, Anthony R.
    Kanate, Abraham S.
    Olteanu, Horatiu
    Hamadani, Mehdi
    Fenske, Timothy S.
    Kenkre, Vaishalee P.
    Svoboda, Jakub
    Cashen, Amanda F.
    Epperla, Narendranath
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (02): : 95 - 102
  • [6] Treatment patterns, and survival of patients with metastatic undifferentiated pleomorphic sarcoma: A National Cancer Database (NCDB) study.
    Rangoonwala, Hussain I.
    Dahl, Mary Elizabeth
    Gootee, Jonathan
    Gundepalli, Sai Giridhar
    Aurit, Sarah J.
    Silberstein, Peter T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Multi-center retrospective study evaluating outcomes of grade 3A follicular lymphoma (FL).
    Greene, Kyle
    Phillips, Tycel Jovelle
    Danilov, Alexey Valeryevich
    Byrne, Michael Thomas
    Cohen, Jonathon Brett
    Kamdar, Manali K.
    Peres-da-Silva, Ashwin
    Churnetski, ichael
    Pan, Zenggang
    Danielson, Nathalie C.
    Kittai, Adam
    Stephens, Deborah Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Treatment outcomes of stage IE intestinal extra-nodal marginal zone lymphoma: A National Cancer Database study.
    Thomes, Reggie M.
    Parsons, Benjamin Marshall
    Borgert, Andrew J.
    Frankki, Susan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Racial Differences in Survival Among Advanced-stage Non-small-Cell Lung Cancer Patients Who Received Immunotherapy: An Analysis of the US National Cancer Database (NCDB)
    Gupta, Anjali
    Zhang, Dongyu
    Braithwaite, Dejana
    Karanth, Shama D.
    Tailor, Tina D.
    Clarke, Jeffrey M.
    Akinyemiju, Tomi
    JOURNAL OF IMMUNOTHERAPY, 2022, 45 (02) : 132 - 137